Symbiotec Pharmalab
· Mainboard · NSE, BSE
Price Band
₹938–988
Lot Size
15 shares
Issue Size
₹1,757 Cr
Min. Investment
₹14,820
Grey Market Premium
Last unofficial quote before listing
Cap price plus current GMP: ₹1173 — arithmetic, not a forecast
Subscription Status
Symbiotec PharmalabIPO: Overview & Key Facts
Symbiotec Pharmalab IPO is a Mainboard issue that listed on NSE, BSE on 1 September 2026. The price band is ₹938–₹988 per equity share, with a market lot of 15 shares. The total issue size is ₹1,757 Cr. At the upper price band, the minimum application for an individual investor is 1 lot (15 shares), amounting to ₹14,820.
Symbiotec Pharmalab IPO GMP & Listing
The last grey market premium (GMP) reported for Symbiotec Pharmalab IPO before listing was ₹185, about 18.72% over the upper price band of ₹988, and informal quotes had eased over the sessions we recorded. The shares opened at ₹988 on listing day, level with the issue price of ₹988. GMP is an unofficial, unregulated indicator quoted by off-market dealers; it moves with supply and demand and is not a guaranteed listing price. For how often it has been right, read our research on IPO GMP accuracy.
Symbiotec PharmalabIPO Subscription Status & Demand Analysis
On the latest figures we have, Symbiotec Pharmalab IPO was subscribed 75.01x overall — with QIB at 181.2x, NII at 77.53x, bNII at 87.34x, sNII at 57.91x, Retail at 13.56x, Employee at 16.2x, from about 52,46,066 applications. Where the individual-investor category is oversubscribed, allotment in it is decided by a computerised lottery: as many applicants as possible receive the minimum application, chosen at random.
Symbiotec Pharmalab IPO Allotment & Listing
The registrar for this issue is MUFG Intime India Pvt. Ltd. (formerly Link Intime); the basis of allotment was finalised on 28 August 2026 and the shares listed on 1 September 2026. You can check your allotment status on our IPO Allotment Checker using your PAN or application number.
Listing Performance
Issue Price
₹988
Listed At
₹988
Current Price
₹1097.7
Issue Objectives
- Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company
- General Corporate Purposes
- Issue Expenses
Reservation
| Category | Shares Offered | % |
|---|---|---|
| QIB | 88,76,516 | 50% |
| − Anchor Investor | 53,25,909 | 0% |
| − QIB (Ex. Anchor) | 35,50,607 | 0% |
| NII (HNI) | 26,62,956 | 15% |
| − bNII > ₹10L | 17,75,304 | 0% |
| − sNII < ₹10L | 8,87,652 | 0% |
| Retail | 62,13,563 | 35% |
| Employee | 33,407 | 0% |
- QIB50.0%
- − Anchor Investor0.0%
- − QIB (Ex. Anchor)0.0%
- NII (HNI)15.0%
- − bNII > ₹10L0.0%
- − sNII < ₹10L0.0%
- Retail35.0%
- Employee0.0%
Market Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 15 | ₹14,820 |
| Retail (Max) | 13 | 195 | ₹1,92,660 |
| S-HNI (Min) | 14 | 210 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1005 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1020 | ₹10,07,760 |
Financials (₹ Cr)
Valuations
EPS (Pre IPO)
17.52
EPS (Post IPO)
17.10
ROE
9.48%
P/E (Pre IPO)
56.39
P/E (Post IPO)
57.78
Market Cap
₹6,198.20 Cr.
Contact Details
Symbiotec Pharmalab Ltd. Address
- +91 731 667 6405
- secretarial@symbiotec.com
- https://www.symbiotec.com/
Registrar Contact Details
MUFG Intime India Pvt. Ltd. (formerly Link Intime)
- +91 22 4918 6270
- ipo.helpdesk@linkintime.co.in
- https://linkintime.co.in
- C-101, 247 Park, LBS Marg, Vikhroli West, Mumbai – 400083
Frequently Asked Questions
Key Dates
- Open Date
- 24 Aug 2026
- Close Date
- 27 Aug 2026
- Basis of Allotment
- 28 Aug 2026
- Listing Date
- 01 Sept 2026
Issue Details
- Registrar
- MUFG Intime India
- Exchange
- NSE, BSE